Istradefylline

[{"orgOrder":0,"company":"Georgetown University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Georgetown University \/ Kyowa Kirin","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Virginia Commonwealth University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Marvel Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":"4","companyTruncated":"Marvel Biosciences \/ iBraiN Institute"}]